Differences in significance of drug resistance mechanisms between adult and childhood acute lymphoblastic leukemia

被引:0
|
作者
Styczynski, J [1 ]
Wysocki, M [1 ]
机构
[1] Med Univ, Dept Pediat Hematol & Oncol, PL-85094 Bydgoszcz, Poland
关键词
acute lymphoblastic leukemia; drug resistance;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Acute lymphoblastic leukemia (ALL) is now curable in 60-80% of children. In adults, in spite of adopting treatment protocols based on therapy for childhood ALL, the disease is still curable in 30-40% of patients only. These worse results of therapy may be due to the induction of various cell defence mechanisms, such as activation of P-glycoprotein, which protects man against xenobiotics. Among a number of various multi-drug resistance mechanisms, differences between adults and children with ALL have been found only for higher P-glycoprotein expression and possibly more often p53 gene mutations in adults. Induction of expression of drug resistance proteins during chemotherapy and co-existence of various mechanisms are common phenomena in adult ALL. Differences in resistance to different drugs might contribute to the impact of age on the outcome of ALL. The underlying mechanisms for these differences are still largely unknown; however, knowledge about drug resistance mechanisms can lead to new therapeutic options.
引用
收藏
页码:313 / 325
页数:13
相关论文
共 50 条
  • [41] Drug resistance in childhood acute myeloid leukemia
    Styczynski, J.
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2007, 8 (02) : 59 - 75
  • [42] Identification of new genes associated with multiple drug resistance in childhood acute lymphoblastic leukemia.
    Lugthart, S
    Cheok, MH
    Den Boer, ML
    Holleman, A
    Yang, WJ
    Pieters, R
    Evans, WE
    BLOOD, 2003, 102 (11) : 137A - 137A
  • [43] Do aberrations in the apoptotic route cause clinical drug resistance in childhood acute lymphoblastic leukemia?
    Holleman, A
    Den Boer, ML
    Kazemier, KM
    Janka-Schaub, GE
    Pieters, R
    LEUKEMIA, 2003, 17 (03) : 670 - 670
  • [44] Evolution of the Epigenetic Landscape in Childhood B Acute Lymphoblastic Leukemia and Its Role in Drug Resistance
    Saint Fleur-Lominy, Shella
    Evensen, Nikki A.
    Bhatla, Teena
    Sethia, Gunjan
    Narang, Sonali
    Choi, Jun H.
    Ma, Xiaotu
    Yang, Jun J.
    Kelly, Stephen
    Raetz, Elizabeth
    Harvey, Richard C.
    Willman, Cheryl
    Loh, Mignon L.
    Hunger, Stephen P.
    Brown, Patrick A.
    Getz, Kylie M.
    Meydan, Cem
    Mason, Christopher E.
    Tsirigos, Aristotelis
    Carroll, William L.
    CANCER RESEARCH, 2020, 80 (23) : 5189 - 5202
  • [45] Ploidy status and drug resistance profiles in childhood acute lymphoblastic leukemia: an analysis of 425 cases
    Ramakers-Van Woerden, NL
    Pieters, R
    Rots, MG
    Kaspers, GJL
    van Wering, ER
    Loonen, AH
    Slater, RM
    Harbott, J
    Schmiegelow, K
    Janka-Schaub, GE
    Veerman, AJP
    LEUKEMIA, 2001, 15 (03) : 506 - 506
  • [46] Immunophenotype in relation to in vitro cellular drug resistance in childhood relapsed acute lymphoblastic leukemia (ALL).
    Kaspers, GJL
    Wijnands, JJM
    Hartmann, R
    Von Stackelberg, A
    Henze, G
    Pieters, R
    Hahlen, K
    Van Wering, ER
    Veerman, AJP
    BLOOD, 2003, 102 (11) : 859A - 860A
  • [47] In Vitro Drug Testing of Barasertib in Childhood Acute Lymphoblastic Leukemia
    Goto, Hiroaki
    Yoshino, Yuki
    Nakamura, Wataru
    Fujita, Sachio
    Miyagawa, Naoyuki
    Hayashi, Akiko
    Yokosuka, Tomoko
    Hamanoue, Satoshi
    Iwasaki, Fuminori
    Shiomi, Masae
    Goto, Shoko
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S35 - S36
  • [48] Clinical significance of aberrant DNA methylation in childhood acute lymphoblastic leukemia
    Takeuchi, Seisho
    Matsushita, Masahide
    Zimmermann, Martin
    Ikezoe, Takayuki
    Komatsu, Naoki
    Seriu, Taku
    Schrappe, Martin
    Bartram, Claus R.
    Koeffler, H. Phillip
    LEUKEMIA RESEARCH, 2011, 35 (10) : 1345 - 1349
  • [49] DIFFERENCES IN DNA-FINGERPRINTS BETWEEN REMISSION AND RELAPSE IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA
    PAKKALA, S
    HELMINEN, P
    SAARINEN, UM
    ALITALO, R
    PELTONEN, L
    LEUKEMIA RESEARCH, 1988, 12 (09) : 757 - 762
  • [50] Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia
    Cavé, H
    ten Bosch, JV
    Suciu, S
    Guidal, C
    Waterkeyn, C
    Otten, J
    Bakkus, M
    Thielemans, K
    Grandchamp, B
    Vilmer, E
    NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09): : 591 - 598